Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

torsion dystonia 17 News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A multicentric observational study reveals significant genotype-phenotype correlations in THAP1-associated dystonia, enhancing understanding of this rare movement disorder. The findings may inform future research and therapeutic strategies.

A case report highlights the correlation between post-operative stun effects captured by local field potentials and temporary symptom relief in an adolescent with dystonia. This finding may provide insights into the mechanisms of symptom management in dystonia patients.

Dystonia Europe emphasizes solidarity and awareness for individuals living with dystonia during Rare Disease Day. The organization continues to advocate for better understanding and support for this condition.

A recent study analyzes the rare variant burden of dystonia-related genes in patients with Parkinson's disease, providing insights into genetic contributions to the condition. This research could inform future therapeutic strategies and genetic testing approaches.

A case report highlights dystonia as an early symptom in a patient with a CYP2U1 gene mutation, expanding the known phenotype of SPG56. This finding may enhance understanding of the disease's clinical presentation.

A novel neurological presentation of CACNA1C-related channelopathy has been identified, manifesting as adult-onset combined dystonia and parkinsonism. This discovery may enhance understanding of the disease's clinical spectrum and inform future research.

Vima has secured $100 million in funding to develop an oral drug aimed at treating movement disorders, specifically targeting dystonia and Parkinson's disease. This investment positions Vima to advance its innovative approach to restoring movement control.

Not rare diseases news,news about your rare disease.